Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.
Authors
- Eric C. Haupt (ORCID: https://orcid.org/0000-0001-8099-2801)
- Erin Elizabeth Hahn (ORCID: https://orcid.org/0000-0002-8419-2331)
- Aasthaa Bansal (ORCID: https://orcid.org/0000-0001-5507-2640)
- J. Felipe Montano-Campos (ORCID: https://orcid.org/0000-0003-0641-2500)
- Jerald P. Radich (ORCID: https://orcid.org/0000-0002-1618-230X)
Institutions
- Kaiser Permanente (US)
- University of Washington (US)
- University of Washington Medical Center (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- JCO Clinical Cancer Informatics
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1200/cci-25-00003
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77